Authors' Reply - Comments: Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?
作者信息
Gomes Luis Eduardo Miani, da Silva Francesca Aparecida Ramos, Pascoal Lívia Bitencourt, Ricci Renato Lazarin, Nogueira Guilherme, Camargo Michel Gardere, de Lourdes Setsuko Ayrizono Maria, Fagundes João José, Leal Raquel Franco
机构信息
Laboratorio de Investigacao em Doencas Inflamatorias Intestinais, Servico de Coloproctologia, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, BR.
Laboratorio de Sinalizacao Celular, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, BR.
出版信息
Clinics (Sao Paulo). 2019 Sep 26;74:e1517. doi: 10.6061/clinics/2019/e1517. eCollection 2019.
Abstract
摘要
相似文献
1
Authors' Reply - Comments: Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?
Clinics (Sao Paulo). 2019 Sep 26;74:e1517. doi: 10.6061/clinics/2019/e1517. eCollection 2019.
2
Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?
Clinics (Sao Paulo). 2019 Sep 26;74:e1424. doi: 10.6061/clinics/2019/e1424. eCollection 2019.
3
Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply.
Lancet. 2017 Dec 2;390(10111):2436. doi: 10.1016/S0140-6736(17)32463-7. Epub 2017 Dec 1.
4
Methotrexate for induction of remission in refractory Crohn's disease.
Cochrane Database Syst Rev. 2012 Dec 12;12:CD003459. doi: 10.1002/14651858.CD003459.pub3.
5
Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease.
Clinics (Sao Paulo). 2019 Apr 8;74:e824. doi: 10.6061/clinics/2019/e824.
6
Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors' reply.
Aliment Pharmacol Ther. 2016 Oct;44(7):772-3. doi: 10.1111/apt.13768.
7
Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' reply.
Aliment Pharmacol Ther. 2020 Sep;52(6):1082. doi: 10.1111/apt.16031.
8
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Cochrane Database Syst Rev. 2008 Jan 23(1):CD006893. doi: 10.1002/14651858.CD006893.
9
Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.
Aliment Pharmacol Ther. 2017 Mar;45(6):856-857. doi: 10.1111/apt.13968.
10
Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease--authors' reply.
Aliment Pharmacol Ther. 2014 Jul;40(1):121-2. doi: 10.1111/apt.12817.
本文引用的文献
1
Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?
Clinics (Sao Paulo). 2019 Sep 26;74:e1424. doi: 10.6061/clinics/2019/e1424. eCollection 2019.
2
Impaired nutritional status in outpatients in remission or with active Crohn's disease - classified by objective endoscopic and imaging assessments.
Clin Nutr ESPEN. 2019 Oct;33:60-65. doi: 10.1016/j.clnesp.2019.07.006. Epub 2019 Aug 8.
3
Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease.
Clinics (Sao Paulo). 2019 Apr 8;74:e824. doi: 10.6061/clinics/2019/e824.
4
SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT.
Arq Gastroenterol. 2018 Apr-Jun;55(2):192-197. doi: 10.1590/S0004-2803.201800000-35.
5
Success and safety of high infliximab trough levels in inflammatory bowel disease.
Scand J Gastroenterol. 2018 Aug;53(8):940-946. doi: 10.1080/00365521.2018.1486882. Epub 2018 Jul 10.
6
Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy.
Gastroenterol Res Pract. 2018 May 8;2018:1952086. doi: 10.1155/2018/1952086. eCollection 2018.
7
Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease.
Inflamm Bowel Dis. 2018 Sep 15;24(10):2266-2271. doi: 10.1093/ibd/izy132.
8
Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.
Aliment Pharmacol Ther. 2018 Feb;47(4):478-484. doi: 10.1111/apt.14458. Epub 2017 Dec 6.
9
IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT.
Arq Gastroenterol. 2017 Dec;54(4):333-337. doi: 10.1590/S0004-2803.201700000-41. Epub 2017 Sep 21.
10
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
Inflamm Bowel Dis. 2017 Nov;23(11):2048-2053. doi: 10.1097/MIB.0000000000001223.
Zotero 插件